Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q1 FY2021 Earnings Presentation
16 slides from Morepen Laboratories's earnings presentation, Aug 31, 2020
Slide 1: Cover letter to stock exchanges: Investors Presentation Q1 FY21
MOREPEN Date: 31/08/2020 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Tel No: (022) 26598100 - 8114 Phones: 91-22-22721233/4 Fax No: (022) 26598120 Fax: 91
Slide 2: Investors Presentation (Q1'FY21) August 2020
“ I CHOOSE INVESTORS PRESENTATION (Q1’FY21) august 2020
Slide 3: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 4: Highlights of Q1'FY21
Highlights of Q1’FY21 Consolidated Performance ₹ crores • Net Revenue in Q1’FY21 up by 27% at Rs. 258.97 crore from Rs. 203.26 crore in Q1’FY20. • Net Profit before tax has jumped by 155% at Rs. 19.56 crore against Rs.7.68 crores in Q1’FY20. • EBDITA has moved up at Rs. 27.90 crore, up 42% from Rs.
Slide 5: Q1 Segment wise growth
Q1 Segment wise growth: ₹ crores • Overall business for the quarter (Q1’FY21) has registered growth of 27% as compared to Q1’FY20 despite market disruptions due to complete lockdown in major markets. 259 • API Business has registered a growth of 44% for the year Q1’FY’21 and has contributed 64% to t
Slide 6: API: Taking the lead
API: Taking the lead API Revenues ₹ crores • API business increases its lion’s share in company’s revenues to 64% and has grown by 44% on Q-o-Q basis despite lockdown in various markets in India and 162.06 abroad. 44% • In the Export market business grew by more than 47% and in the Domestic market a
Slide 7: Regulated Markets Exports Soared
Regulated Markets Exports Soared ₹ crores • Asia pacific Export business has got 57% share in the export business for the year FY’21 and a good growth of 45% as compared to FY’20. 117 47% • Europe market has shown spectacular increase of 127%, USA business has down by 20% this quarter due to lockdow
Slide 8: Mega Expansion plan- Rs.178 crores
Mega Expansion plan- Rs.178 crores • Company’s Board has approved a mega expansion plan involving an outlay of Rs. 178 crore for existing products and the strong pipeline of APIs under development. • The plan has already been approved by Himachal State Government under single window clearance scheme
Slide 9: Devices Business – Performance
Devices Business – Performance ₹ crores • Home Devices portfolio has achieved a good growth of 16% during the quarter compared to 46.56 corresponding period last year. In order to fight the Covid-19 battle, company launched Non- Contact Infrared Thermometers in the month of April 2020. 16% • Thermom
Slide 10: New Launches: Oxygen Concentrator for Covid Care
New Launches: Oxygen Concentrator for Covid Care 9
Slide 11: OTC Business Shines all the way
OTC Business Shines all the way ₹ crores • OTC category in total has been able to score a stunning growth of 53% during the quarter on the strength of 50% growth in grooming business and introduction of Covid range of products. 21.69 53% • The Company launched a wide range of, hand sanitizers, hand
Slide 12: The Joy Of Growing Together
‘The Joy Of Growing Together Your Beauty Solution For Skin Ageing “ ING Tarr OLLACE! Y Skin Firmn v Hydration = ¥ Glow [== ¥ Reduce Fine Lines & Pores
Slide 13: Profit after tax jumps 153%
Profit after tax jumps 153% ₹ crores Consolidated • EBIDTA has scaled up from Rs. 19.61 crores to Rs. 27.90 crores, a significant jump of 42% Revenue during the year Q1’FY21 on account of increased topline and controlled expenses. 258.97 • Cash Profits during the year Q1’FY21 has also taken a leap o
Slide 14: Q1'FY21 Performance - Standalone
Q1’FY21 Performance - Standalone ₹ crores Q-o-Q Particulars Q1’FY21 Q1’FY20 Growth Net Revenue 244.58 189.75 28.89% Expenditure 217.98 170.02 28.20% EBIDTA 26.60 19.73 34.85% Interest 0.28 0.42 (32.33%) Cash Surplus 26.32 19.31 36.32% Dep. & Amortization 7.47 10.90 (31.45%) Profit before Tax 18.85 8
Slide 15: Q1'FY21 Performance - Consolidated
Q1’FY21 Performance - Consolidated ₹ crores Q-o-Q Particulars Q1’FY21 Q1’FY20 Growth Net Revenue 258.97 203.26 27.40% Expenditure 231.07 183.65 25.81% EBIDTA 27.90 19.61 (42.26%) Interest 0.29 0.43 (33.27%) Cash Surplus 27.61 19.18 43.94% Dep. & Amortization 8.05 11.50 (29.95%) Profit before Tax 19.
Slide 16: Thank You
Tran You * MOREPEN The Joy Of Growing Together
Morepen Laboratories — Q1 FY2021 Earnings Presentation on 6ix